Medscape4d
Pharmacologic Management of Heart Failure with Preserved Ejection Fraction
An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...
thecardiologyadvisor.com1d
In HF With Preserved LVEF, Ventura Interatrial Shunt Not Associated With Improved Outcomes
Transcatheter implantation of the Ventura interatrial shunt is safe but does not lead to improved clinical outcomes in patients with heart failure (HF) and preserved left ventricular ejection fraction ...
Medscape2d
How Do Patients With Heart Failure With Preserved Ejection Fraction Die?
Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...
The New England Journal of Medicine20d
Finerenone in Heart Failure with Preserved Ejection Fraction
Therapies are needed for patients with heart failure with mildly reduced or preserved ejection fraction. New research findings on the nonsteroidal mineralocorticoid receptor antagonist finerenone ...
WebMD1mon
What Does Ejection Fraction Have to Do With Heart Failure?
A low ejection fraction lets a doctor know that the active pumping phase of the heart isn't working. It's usually tied to some, but not all, types of heart failure. Heart failure with a low EF is ...
thecardiologyadvisor.com6d
Finerenone Reduces Heart Failure Events, Improves Health Status in HFmrEF, HFpEF
Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.
Health.com9d
What To Know about Systolic Congestive Heart Failure
Systolic heart failure happens when the heart pumps at 40% or less of its ejection fraction. Ejection fraction measures how much blood the heart pumps with each contraction or beat. Systolic heart ...
Pharmabiz1d
Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024
TX45 is being evaluated in the APEX phase 2 clinical trial (NCT06616974) in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). The trial is ...
Renal & Urology News6d
Finerenone May Not Slow Kidney Function Decline in Patients With Heart Failure
Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...
8 Common Cardiovascular Diseases for Men & How to Prevent Them
Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...
Business Insider2d
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
About the APEX Phase 2 Clinical Trial for TX45 in Pulmonary Hypertension with HFpEF TX45 is being evaluated in the APEX Phase 2 clinical trial (NCT06616974) in patients with Group 2 Pulmonary ...